



## Telesis Bio to Present at Festival of Biologics Conference

March 16, 2023

### **Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions”**

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced Daniel Gibson, Ph.D., CTO and Co-founder of Telesis Bio will present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions” at the upcoming Festival of Biologics conference on March 21, 2023.

In this presentation Dr. Gibson will discuss Telesis Bio's solutions to remove workflow bottlenecks and accelerate lead discovery. The discussion will include the award winning BioXp® platform that enables hands-free overnight synthesis of lead candidates, and a new generation of enzymatic DNA synthesis, SOLA (short oligonucleotide ligation assembly), which delivers robust and reproducible oligo synthesis on demand.

Telesis Bio's unique SOLA approach addresses many of the challenges facing existing EDS methods related to build length, cost, fidelity, and scalability into synthetic biology workflows. Unlike alternative technologies that employ terminal deoxynucleotidyl transferase (TdT), which incorporates one DNA letter at a time, the streamlined SOLA process generates high-quality synthetic DNA from a universal, pre-manufactured library of short DNA oligos.

“The short oligos provide the building blocks needed to efficiently assemble complex synthetic genes and mRNA templates using Telesis Bio's industry-standard Gibson Assembly® method on the automated BioXp system.” Said Daniel Gibson, Ph.D., CTO and Co-founder of Telesis Bio. “Together, the SOLA technology and BioXp system have the potential to significantly reduce timelines for constructing synthetic DNA, RNA, and proteins for numerous downstream applications including vaccine development, therapeutics development, diagnostics, precision medicine, and DNA data storage.”

For more information on the BioXp® system please visit [telesisbio.com/products/bioxp-system/](https://telesisbio.com/products/bioxp-system/)

To learn more about SOLA please visit [telesisbio.com/innovation/sola-technology/](https://telesisbio.com/innovation/sola-technology/)

### **About Telesis Bio**

Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity's greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit [www.telesisbio.com](https://www.telesisbio.com).

Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

### **Forward-Looking Statements**

*This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio's future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 11, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.*

### **Contact:**

Jen Carroll

Vice President of Investor Relations

[jen.carroll@telesisbio.com](mailto:jen.carroll@telesisbio.com)